000283026 001__ 283026
000283026 005__ 20251222102252.0
000283026 0247_ $$2doi$$a10.1515/medgen-2024-2066
000283026 0247_ $$2ISSN$$a0936-5931
000283026 0247_ $$2ISSN$$a1863-5490
000283026 037__ $$aDZNE-2025-01438
000283026 082__ $$a610
000283026 1001_ $$0P:(DE-2719)9003523$$aZeng, Leopold Hongming$$b0$$udzne
000283026 245__ $$aLeber’s hereditary optic neuropathy – current status of idebenone and gene replacement therapies
000283026 260__ $$aBerlin$$bde Gruyter$$c2025
000283026 3367_ $$2DRIVER$$aarticle
000283026 3367_ $$2DataCite$$aOutput Types/Journal article
000283026 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766395029_14399
000283026 3367_ $$2BibTeX$$aARTICLE
000283026 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283026 3367_ $$00$$2EndNote$$aJournal Article
000283026 520__ $$aLeber’s hereditary optic neuropathy (LHON) is the most common mitochondrial disease, and was the first to be linked to mitochondrial DNA (mtDNA) variations. Recently, autosomal recessive forms of LHON were described in addition to the classical mtDNA-associated forms. Clinically, LHON manifests with subacute and painless loss of central visual acuity, in most cases starting unilaterally, and involving the second eye a few weeks later. Almost all LHON cases are caused by pathogenic variants in genes that code for proteins relevant for function of Complex I of the respiratory chain. The Complex I dysfunction in LHON leads to decreased ATP synthesis and to increased production of reactive oxygen species which ultimately initiates dysfunction and apoptosis of retinal ganglion cells and their axons, the optic nerve. Idebenone, a synthetic CoQ derivative, is a potent intramitochondrial antioxidant and can shuttle electrons directly to complex III of the respiratory chain, thereby bypassing complex I deficiency. On the basis of several clinical trials, it has been approved as a treatment for LHON in 2015 (in the EU). In addition, direct intravitreal gene replacement therapy is being investigated, with several late-stage clinical trials already completed. In the future, gene editing of mtDNA variants may also become a therapeutic option.
000283026 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283026 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283026 7001_ $$00000-0003-1847-3626$$aPriglinger, Claudia$$b1
000283026 7001_ $$0P:(DE-2719)2810704$$aKlopstock, Thomas$$b2$$eLast author$$udzne
000283026 773__ $$0PERI:(DE-600)2163157-8$$a10.1515/medgen-2024-2066$$gVol. 37, no. 1, p. 57 - 63$$n1$$p57 - 63$$tMedizinische Genetik$$v37$$x0936-5931$$y2025
000283026 8564_ $$uhttps://pub.dzne.de/record/283026/files/DZNE-2025-1438.pdf$$yRestricted
000283026 8564_ $$uhttps://pub.dzne.de/record/283026/files/DZNE-2025-1438.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283026 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003523$$aExternal Institute$$b0$$kExtern
000283026 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810704$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283026 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283026 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-04$$wger
000283026 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMED GENET-BERLIN : 2022$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-04
000283026 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-04
000283026 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000283026 980__ $$ajournal
000283026 980__ $$aEDITORS
000283026 980__ $$aVDBINPRINT
000283026 980__ $$aI:(DE-2719)1111015
000283026 980__ $$aUNRESTRICTED